CD19/BCMA-Targeted Chimeric Antigen Receptor-T Cell Therapy for Anti-HLA Antibody Sensitisation in Patients With Acute Leukaemia: A Pilot Clinical Study.
AI interpretation is pending for this paper.
Open original publication →What the AI sees
Not AI summarized yet.
Research significance
Pending deeper interpretation.
Source abstract
Antibodies targeting foreign HLA molecules can be detrimental in transplantation. Nonetheless, existing desensitisation methods for anti-HLA antibodies frequently prove insufficient. We conducted a single-arm pilot study to evaluate CD19/B cell maturation antigen (BCMA) chimeric antigen receptor T (CAR-T) cell therapy for desensitising anti-HLA antibodies prior to transplantation. Seven patients diagnosed with acute leukaemia participated in the study, comprising four individuals with acute myeloid leukaemia (AML) and three with acute B lymphoblastic leukaemia (B-ALL). Among them, one patient was treated with BCMA CAR-T cells, while six received CD19 CAR-T cells. No instances of neurotoxicity or severe cytokine release syndrome (grade ≥ 3) were noted. CAR-T cell expansion was observed in six patients (86%), with the exception of patient 3. Among the seven patients with pre-infusion anti-HLA-I antibodies, five (71%) showed a decrease in mean fluorescence intensity (MFI), including three (43%) who experienced a reduction greater than 75%. Among the six patients confirmed to exhibit CAR-T cell expansion in vivo, three presented with donor-specific anti-HLA antibodies (DSAs) prior to CAR-T cell infusion. The median MFI level of DSA declined from 15797.8 (7750.3-21106.0) to 3831.1 (523.3-13197.0) (p < 0.001) in the three patients studied. Two patients with decreased DSA levels after CD19 CAR-T cell infusion underwent combined desensitisation before haematopoietic stem cell transplantation. This pilot study illustrates the potential safety and efficacy of CD19 and BCMA CAR-T cells in desensitising anti-HLA antibodies in patients with AML or B-ALL. However, only one patient received BCMA CAR-T cells in our cohort, so further research with an expanded sample size is essential for comprehensively evaluating the safety and efficacy of CD19/BCMA CAR-T cell therapy for anti-HLA antibody sensitisation.